- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04696705
Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients
January 5, 2021 updated by: Zou Dehui, Institute of Hematology & Blood Diseases Hospital
The Safety and Efficacy Assessment of Ex-Vivo Expanded Allogeneic γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) and Peripheral T Cell Lymphomas (PTCL)
This study aims to evaluate the safety, tolerability and efficacy of ex-vivo expanded allogeneic γδT cells obtained from a blood-related donor of patients with relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL) or peripheral T cell lymphoma (PTCL) expect for γδT lymphoma.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
This study is a single-center, non-randomized, open label, no control, prospective clinical trial to evaluate the safety, tolerability and efficacy of ex-vivo expanded allogeneic γδT cells from a blood-related donor of NHL or PTCL patients(except for γδT lymphoma).
This study will include the following sequential phases: sign informed consent, γδT cell pre-culture, screening and registration to the trial, apheresis, γδT cell preparation, pre-treatment for lymphodepleting chemotherapy (selectable plan), treatments and follow-ups.
The study will evaluate the safety and efficacy of the ex-vivo expanded allogeneic γδT cells in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) or peripheral T cell lymphoma (PTCL) expect for γδT lymphoma.
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dehui Zou, MD
- Phone Number: 86-022-23909283
- Email: zoudehui@ihcams.ac.cn
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300020
- Recruiting
- Institute of Hematology & Blood Disease Hospital
-
Contact:
- Shuhua Yi, MD
- Phone Number: 86-022-23909106
- Email: yishuhua@ihcams.ac.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patient Inclusion Criteria:
- Patients should sign informed consent form voluntarily before the trail and comply with the requirements of this study.
- Age≥18 years old, gender unlimited.
- Patients whose relatives are willing to donate PBMCs voluntarily.
- Patients with relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL) or peripheral T cell lymphoma (PTCL) expect for γδT lymphoma.
- Patients had an evaluable imaging lesion of at least greater than 1.5 cm.
- Eastern Cooperative Oncology Group (ECOG) Performance score≤2.
Adequate bone marrow function:
- Absolute neutrophil count (ANC) >1000/mm3;
- Absolute lymphocyte count (ALC)≥300/mm3;
- PLT≥50,000/mm3;
- Hb >8.0g/dl.
Adequate organ function:
- Alanine aminotransferase (ALT)≤3 times the upper limit of normal (ULN);
- Aspartate aminotransferase (AST)≤3 times ULN
- TBIL≤1.5 times ULN (Gilbert syndrome patients TBIL≤3 times ULN and DBIL≤1.5 times ULN)
- Scr≤1.5 times ULN or CCR≥60 mL/min/1.73m3 Note: apart from tumor infiltrated liver dysfunction.
- Male and female patients of reproductive potential must agree to use birth control during the study and for at least 12 weeks post study.
Donor Inclusion Criteria:
- Sign informed consent form.
- Age 18 years up to the age of 60 (≤60), gender unlimited.
- Relatives of patients (unrestricted to blood relationship).
- Apheresis available.
- PLT≥100×109/L with normal APTT or PT.
Exclusion Criteria:
Patient Exclusion Criteria:
- Patients with other available treatment drugs or treatment options.
- Patients with history of allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
- Active central nervous system (CNS) lymphoma.
Patients receiving chemotherapy within 1 week prior to γδT cell transfusion, with the following exceptions:
- Pretreatment chemotherapy prescribed by the protocol
- Other exploratory combined medications
- Systemic glucocorticoid treatment 72h prior to γδT cell transfusion (apart from physiological replacement dosage).
- Biphosphonates were used 2 months prior to γδT cell transfusion.
- Patients with systemic vasculitis, or with active or uncontrolled autoimmune diseases, as well as primary or secondary immunodeficiency diseases.
- Active HBV, HCV, HIV, TP, CMV or EBV infection.
- Major surgery that was evaluated by the investigator as unsuitable for inclusion within 4 weeks prior to screening.
- Patients with malignant tumors, apart from those who has been cured for at least 2 years.
Patient's cardiac function meets any of the following conditions:
- Left ventricular ejection fraction (LVEF)≤45%
- Class III or IV heart failure according to the NYHA Heart Failure Classifications
- QTcB>450 msec
- Other cardiac disease that investigators judge is not suitable for enrollment
- History of epilepsy or other active central nervous system disorders.
- Inoculated live vaccine within 6 weeks before screening.
- Uncontrolled serious active infection (such as sepsis, bacteremia and fungemia).
- Life expectancy < 3 months
- Participated in any other interventional clinical trial within 3 months prior to γδT cell transfusion.
- Any situation that investigators believe the risk of the subjects is increased or results of the trial are disturbed: patients with any serious acute or chronic physical or mental illness, or laboratory abnormalities.
Donor Exclusion Criteria:
- History of any severe clinical diseases or other severe organic diseases, including any history of clinically significant systematic diseases such as cardiovascular, urinary, circulatory, respiratory, neurological, psychiatric, digestive and endocrine diseases. History of high blood pressure or systolic pressure>140 mmHg, diastolic pressure>90 mmHg in screening stage. Any situation that investigators believe is clinically significant or with other severe diseases unsuitable of apheresis.
- Arterial thrombosis or venous thrombosis history 12 months prior to the trial or hemorrhagic tendency or history 2 months prior to the trial; oral administration of anticoagulation drugs (e. g. aspirin and warfarin).
- Active or history of autoimmune diseases including but not restricted to SLE, psoriasis, RA, IBD and HT. Apart from hypothyrosis which can be controlled by hormone replacement therapy, skin diseases without systemic therapy and celiac disease which is fully controlled.
- HIV-Ab, TP-Ab, HCV-Ab, HBsAg, HBeAg, HBeAb or HBcAb positive.
- Any symptom, sign or laboratory examination abnormality suggesting acute or subacute infection (e.g. fever, cough, urinary irritation, skin infectious wound).
- Female who are pregnant or cannot stop lactating.
- Those who cannot communicate with medical staff due to mental illness or language disabilities.
- Other unsuitable conditions that investigators believe unsuitable for the donation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Allogeneic γδT cell immunotherapy
Patients will receive 2 cycles of ex-vivo expanded allogeneic γδT cells treatments, at 14 days' intervals, each cycle has 2 infusions.
Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
|
Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation.
The ex-vivo expanded γδT cells from donors will be adoptively transfused.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety evaluation: Incidence of Adverse events (AEs)
Time Frame: 2 years post γδT cells infusion
|
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).
|
2 years post γδT cells infusion
|
Safety evaluation: Dose limited toxicity (DLTs)
Time Frame: 28 days
|
The incidence of DLTs will be recorded and assessed.
|
28 days
|
Safety evaluation: Maximum-tolerated dose (MTD)
Time Frame: 28 days
|
MTD or clinical recommended dose will be recorded and evaluated.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy evaluation:Overall response rate (ORR)
Time Frame: 2 years post γδT cells infusion
|
ORR is defined as the incidence of either a CR or a partial response (PR) per the Lugano Classification as determined by study investigators.
|
2 years post γδT cells infusion
|
Efficacy evaluation:Disease control rate (DCR)
Time Frame: 2 years post γδT cells infusion
|
DCR is defined as the incidence of either a CR, a partial response (PR) or stable disease (SD) per the Lugano Classification as determined by study investigators.
|
2 years post γδT cells infusion
|
Efficacy evaluation:Duration of remission (DOR)
Time Frame: 2 years post γδT cells infusion
|
DOR is defined only for participants who experience an objective response after γδT cells infusion and is the time from the first objective response to disease progression or death from any cause.
|
2 years post γδT cells infusion
|
Efficacy evaluation:Progression free survival (PFS)
Time Frame: 2 years post γδT cells infusion
|
PFS is defined as the time from the γδT cells infusion date to the date of disease progression or death from any cause.
|
2 years post γδT cells infusion
|
Efficacy evaluation:Overall survival (OS)
Time Frame: 2 years post γδT cells infusion
|
OS is defined as the time from γδT cells infusion to the date of death from any cause.
|
2 years post γδT cells infusion
|
Pharmacokinetics (PK) evaluation :γδT cells in peripheral blood
Time Frame: 2 years post γδT cells infusion
|
Number of γδT cells in peripheral blood will be assessed by flow cytometry.
|
2 years post γδT cells infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Jianmin Zhang, PhD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 31, 2020
Primary Completion (Anticipated)
December 25, 2021
Study Completion (Anticipated)
December 25, 2023
Study Registration Dates
First Submitted
December 23, 2020
First Submitted That Met QC Criteria
January 5, 2021
First Posted (Actual)
January 6, 2021
Study Record Updates
Last Update Posted (Actual)
January 6, 2021
Last Update Submitted That Met QC Criteria
January 5, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIT2020028-EC-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's Lymphoma (NHL)
-
Sun Yat-sen UniversityRecruitingRelapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)China
-
Gilead SciencesCompleted
-
Shanghai Miracogen Inc.RecruitingRelapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)China
-
Cullinan Oncology Inc.RecruitingA Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)NHL | NHL, Relapsed, AdultUnited States
-
University of PennsylvaniaCompletedNon-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell LymphomasUnited States
-
German High-Grade Non-Hodgkin's Lymphoma Study...Deutsche Krebshilfe e.V., Bonn (Germany)CompletedNon-Hodgkin's Lymphoma (NHL)Germany
-
Bioray LaboratoriesFirst Affiliated Hospital of Zhejiang University; The First Affiliated Hospital... and other collaboratorsSuspendedAcute Lymphoblastic Leukemia (ALL) | Non Hodgkin Lymphoma (NHL)China
-
Mundipharma Research LimitedTerminatedIndolent B-cell NHLAustralia, Slovakia
-
Czech Lymphoma Study GroupRecruitingNon Hodgkin Lymphoma (NHL)Czechia
-
Gilead SciencesWithdrawnDiffuse Large B-cell Lymphoma | NHL | Non Hodgkin's Lymphoma | Aggressive NHLUnited States
Clinical Trials on Ex-vivo expanded allogeneic γδT cells
-
Beijing 302 HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...UnknownHepatocellular CarcinomaChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
Dartmouth-Hitchcock Medical CenterThe Leukemia and Lymphoma SocietyCompletedMyeloma | Transplant-eligible PatientsUnited States
-
King Edward Medical UniversityUnknownLipodystrophy | Craniofacial Microsomia | Mixed Connective Tissue Disease | Romberg's Disease
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States
-
Nationwide Children's HospitalCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IIUnited States
-
Singapore General HospitalWhitehead Institute for Biomedical Research; Blood Services Group, Health Sciences...TerminatedLymphoma | Acute Leukemia | Myelodysplastic Syndrome | Myeloma | Chronic LeukemiaSingapore
-
Jeffrey BluestoneNational Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance...TerminatedAcute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoVUnited States
-
Wuhan Union Hospital, ChinaJinan University, ChinaUnknownAcute Myeloid LeukemiaChina
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Juvenile Diabetes...CompletedType 1 Diabetes MellitusUnited States